Celebrating the 10th anniversary partnership with BMC
2018 marks the 10th anniversary of the partnership between the Journal of Experimental & Clinical Cancer Research and BMC.
Over the past decade, the journal has established itself among some of the top Oncology titles in Journal Citation Reports. Click here to look back at some of the journal’s milestone achievements and best content from the past 10 years.
Featured Article: The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance
Epidermal growth factor receptor (EGFR) elicits a role in cell survival, differentiation, growth and tumorigenesis. Dysregulation of this receptor has been well documented in cancer progression. It has also been well established that reactive oxygen species (ROS) have a significant involvement in the initiation and regulation of cancer. Formation of oxidative stress as a result of ROS, is thought to participate in tumorigenesis by regulating the EGFR signalling pathways.
In this review, M. Weng et al. discuss the latest evidence surrounding the interactions between ROS and the EGFR signaling pathway to help understand how modulation of ROS can control drug resistance to, and the development of, cancer.
Click here to access the full article.
Click here to access all of the reviews published to date in Journal of Experimental & Clinical Cancer Research.
Aims and scope
Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.
Please click here to read more.
Articles
Meeting reports now accepted
Journal of Experimental & Clinical Cancer Research now welcomes the submission of Meeting reports to help showcase novel developments presented at meetings and conferences.
Please click here for more information on the article types accepted by Journal of Experimental & Clinical Cancer Research.
Editor-in-Chief
Mauro Castelli, Regina Elena National Cancer Institute, Italy
If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to:
2017 Impact Factor
We are delighted to share with our readers that Journal of Experimental & Clinical Cancer Research has an Impact Factor of 6.217 and is currently ranked at 33 out of 222 (Q1) in the Oncology category of Journal Citation Reports (Clarivate Analytics, 2018).
We would like to extend our appreciation to all Editorial Board Members, authors and peer reviewers who have contributed to the journal and enabled this achievement.
Archival content
Journal of Experimental & Clinical Cancer Research has been publishing since 1982. Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print. For enquiries about previous content, please contact us on:
Reviewer Acknowledgement
The editorial team of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal.
Click here to visit the Reviewer acknowledgements page.
Advertisement
-
-
Owned by the Association for International Promotion & Study in Tumors (APSIT)
-
Official journal of the Regina Elena National Cancer Institute, Italy
-
- Editorial Board
- Sign up for article alerts and news from this journal
Follow
2017 Journal Metrics
-
Speed
30 days from submission to first decision
89 days from submission to acceptance
14 days from acceptance to publicationCitation Impact
6.217 - 2-year Impact Factor
5.280 - 5-year Impact Factor
1.350 - Source Normalized Impact per Paper (SNIP)
2.000 - SCImago Journal Rank (SJR)Usage
599,727 Downloads
364 Altmetric Mentions
Advertisement
